Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry.

Gourh P, Safran SA, Alexander T, Boyden SE, Morgan ND, Shah AA, Mayes MD, Doumatey A, Bentley AR, Shriner D, Domsic RT, Medsger TA Jr, Ramos PS, Silver RM, Steen VD, Varga J, Hsu V, Saketkoo LA, Schiopu E, Khanna D, Gordon JK, Kron B, Criswell LA, Gladue H, Derk CT, Bernstein EJ, Bridges SL Jr, Shanmugam VK, Kolstad KD, Chung L, Kafaja S, Jan R, Trojanowski M, Goldberg A, Korman BD, Steinbach PJ, Chandrasekharappa SC, Mullikin JC, Adeyemo A, Rotimi C, Wigley FM, Kastner DL, Boin F, Remmers EF.

Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):552-562. doi: 10.1073/pnas.1906593116. Epub 2019 Dec 23.

2.

Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1).

Mecoli CA, Perin J, Van Eyk JE, Zhu J, Fu Q, Allmon AG, Rao Y, Zeger S, Wigley FM, Hummers LK, Shah AA.

Clin Rheumatol. 2019 Dec 19. doi: 10.1007/s10067-019-04863-0. [Epub ahead of print]

PMID:
31858338
3.

Pharmacotherapy Options in the Management of Raynaud's Phenomenon.

Hinze AM, Wigley FM.

Curr Treatm Opt Rheumatol. 2018 Sep;4(3):235-254. doi: 10.1007/s40674-018-0102-6. Epub 2018 Jul 4.

4.

Longitudinal assessment of interstitial lung disease in single lung transplant recipients with scleroderma.

Hinze AM, Lin CT, Hussien AF, Perin J, Venado A, Golden JA, Boin F, Brown RH, Wise RA, Wigley FM.

Rheumatology (Oxford). 2019 Aug 27. pii: kez341. doi: 10.1093/rheumatology/kez341. [Epub ahead of print]

PMID:
31504916
5.

Epigenetic activation and memory at a TGFB2 enhancer in systemic sclerosis.

Shin JY, Beckett JD, Bagirzadeh R, Creamer TJ, Shah AA, McMahan Z, Paik JJ, Sampedro MM, MacFarlane EG, Beer MA, Warren D, Wigley FM, Dietz HC.

Sci Transl Med. 2019 Jun 19;11(497). pii: eaaw0790. doi: 10.1126/scitranslmed.aaw0790.

PMID:
31217334
6.

Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study.

Kwakkenbos L, Thombs BD, Khanna D, Carrier ME, Baron M, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mayes MD, Mouthon L, Nielson WR, Poiraudeau S, Riggs R, Sauvé M, Wigley F, Hudson M, Bartlett SJ.

Rheumatology (Oxford). 2019 Jun 5. pii: kez234. doi: 10.1093/rheumatology/kez234. [Epub ahead of print] No abstract available.

PMID:
31168593
7.

Clinical and Molecular Phenotyping in Scleromyxedema Pre- and Post-Treatment with Intravenous Immunoglobulin.

Mecoli CA, Talbot CC Jr, Fava A, Cheadle C, Boin F, Wigley FM, Hummers LK.

Arthritis Care Res (Hoboken). 2019 Apr 22. doi: 10.1002/acr.23908. [Epub ahead of print]

PMID:
31008568
8.

Morphea and systemic sclerosis are associated with an increased risk for melanoma and nonmelanoma skin cancer.

Boozalis E, Shah AA, Wigley F, Kang S, Kwatra SG.

J Am Acad Dermatol. 2019 May;80(5):1449-1451. doi: 10.1016/j.jaad.2018.10.022. Epub 2018 Oct 21. No abstract available.

PMID:
30352282
9.

ANCA-associated vasculitis in scleroderma: A renal perspective
.

Kant S, Shah AA, Hummers LK, Wigley FM, Geetha D.

Clin Nephrol. 2018 Dec;90(6):413-418. doi: 10.5414/CN109445.

PMID:
30106367
10.

Vascular complications in systemic sclerosis: a prospective cohort study.

Mecoli CA, Shah AA, Boin F, Wigley FM, Hummers LK.

Clin Rheumatol. 2018 Sep;37(9):2429-2437. doi: 10.1007/s10067-018-4148-5. Epub 2018 May 26.

11.

Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans.

Gourh P, Remmers EF, Boyden SE, Alexander T, Morgan ND, Shah AA, Mayes MD, Doumatey A, Bentley AR, Shriner D, Domsic RT, Medsger TA Jr, Steen VD, Ramos PS, Silver RM, Korman B, Varga J, Schiopu E, Khanna D, Hsu V, Gordon JK, Saketkoo LA, Gladue H, Kron B, Criswell LA, Derk CT, Bridges SL Jr, Shanmugam VK, Kolstad KD, Chung L, Jan R, Bernstein EJ, Goldberg A, Trojanowski M, Kafaja S, Maksimowicz-McKinnon KM, Mullikin JC, Adeyemo A, Rotimi C, Boin F, Kastner DL, Wigley FM.

Arthritis Rheumatol. 2018 Oct;70(10):1654-1660. doi: 10.1002/art.40541. Epub 2018 Aug 29.

12.

Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer.

Igusa T, Hummers LK, Visvanathan K, Richardson C, Wigley FM, Casciola-Rosen L, Rosen A, Shah AA.

Ann Rheum Dis. 2018 Aug;77(8):1179-1186. doi: 10.1136/annrheumdis-2018-212999. Epub 2018 Apr 20.

13.

Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis.

Ahuja NK, Mische L, Clarke JO, Wigley FM, McMahan ZH.

Semin Arthritis Rheum. 2018 Aug;48(1):111-116. doi: 10.1016/j.semarthrit.2017.12.007. Epub 2018 Jan 5.

PMID:
29397195
14.

Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database.

Morgan ND, Shah AA, Mayes MD, Domsic RT, Medsger TA Jr, Steen VD, Varga J, Carns M, Ramos PS, Silver RM, Schiopu E, Khanna D, Hsu V, Gordon JK, Gladue H, Saketkoo LA, Criswell LA, Derk CT, Trojanowski MA, Shanmugam VK, Chung L, Valenzuela A, Jan R, Goldberg A, Remmers EF, Kastner DL, Wigley FM, Gourh P, Boin F.

Medicine (Baltimore). 2017 Dec;96(51):e8980. doi: 10.1097/MD.0000000000008980.

15.

Right Ventricular Myofilament Functional Differences in Humans With Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension.

Hsu S, Kokkonen-Simon KM, Kirk JA, Kolb TM, Damico RL, Mathai SC, Mukherjee M, Shah AA, Wigley FM, Margulies KB, Hassoun PM, Halushka MK, Tedford RJ, Kass DA.

Circulation. 2018 May 29;137(22):2360-2370. doi: 10.1161/CIRCULATIONAHA.117.033147. Epub 2018 Jan 19.

16.

Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer.

Shah DJ, Hirpara R, Poelman CL, Woods A, Hummers LK, Wigley FM, Wright JL, Parekh A, Steen VD, Domsic RT, Shah AA.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1517-1524. doi: 10.1002/acr.23505.

17.

Determining the Risk Factors and Clinical Features Associated With Severe Gastrointestinal Dysmotility in Systemic Sclerosis.

McMahan ZH, Paik JJ, Wigley FM, Hummers LK.

Arthritis Care Res (Hoboken). 2018 Sep;70(9):1385-1392. doi: 10.1002/acr.23479. Epub 2018 Aug 6.

18.

Treating Raynaud phenomenon: Beyond staying warm.

Shapiro SC, Wigley FM.

Cleve Clin J Med. 2017 Oct;84(10):797-804. doi: 10.3949/ccjm.84a.17025. Review.

19.

Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames).

Seibold JR, Wigley FM.

Arthritis Rheumatol. 2017 Dec;69(12):2256-2258. doi: 10.1002/art.40307. Epub 2017 Nov 10. No abstract available.

20.

Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease.

Shah AA, Rosen A, Hummers LK, May BJ, Kaushiva A, Roden RBS, Armstrong DK, Wigley FM, Casciola-Rosen L, Visvanathan K.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):71-74. Epub 2017 Jun 19.

21.

Association of Fibrosing Myopathy in Systemic Sclerosis and Higher Mortality.

Paik JJ, Wigley FM, Shah AA, Corse AM, Casciola-Rosen L, Hummers LK, Mammen AL.

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1764-1770. doi: 10.1002/acr.23291.

22.

Reply.

Shah AA, Rosen A, Hummers LK, Wigley FM, Xu G, Elledge SJ, Casciola-Rosen L.

Arthritis Rheumatol. 2017 Sep;69(9):1915-1916. doi: 10.1002/art.40132. Epub 2017 Jul 11. No abstract available.

23.

Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study.

Kwakkenbos L, Thombs BD, Khanna D, Carrier ME, Baron M, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mayes MD, Mouthon L, Nielson WR, Poiraudeau S, Riggs R, Sauvé M, Wigley F, Hudson M, Bartlett SJ; SPIN Investigators.

Rheumatology (Oxford). 2017 Aug 1;56(8):1302-1311. doi: 10.1093/rheumatology/kex055.

24.

The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Bello RJ, Cooney CM, Melamed E, Follmar K, Yenokyan G, Leatherman G, Shah AA, Wigley FM, Hummers LK, Lifchez SD.

Arthritis Rheumatol. 2017 Aug;69(8):1661-1669. doi: 10.1002/art.40123. Epub 2017 Jun 26.

25.

Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma.

Shah AA, Xu G, Rosen A, Hummers LK, Wigley FM, Elledge SJ, Casciola-Rosen L.

Arthritis Rheumatol. 2017 Jun;69(6):1306-1312. doi: 10.1002/art.40065.

26.

Exhaled nitric oxide in pulmonary arterial hypertension associated with systemic sclerosis.

Cao Z, Mathai SC, Hummers LK, Shah AA, Wigley FM, Lechtzin N, Hassoun PM, Girgis RE.

Pulm Circ. 2016 Dec;6(4):545-550. doi: 10.1086/688768.

27.

Update of EULAR recommendations for the treatment of systemic sclerosis.

Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U; EUSTAR Coauthors.

Ann Rheum Dis. 2017 Aug;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909. Epub 2016 Nov 9.

28.

Independent Association of Severity of Muscle Weakness With Disability as Measured by the Health Assessment Questionnaire Disability Index in Scleroderma.

Paik JJ, Wigley FM, Mejia AF, Hummers LK.

Arthritis Care Res (Hoboken). 2016 Nov;68(11):1695-1703. doi: 10.1002/acr.22870. Epub 2016 Oct 9.

29.

Raynaud's Phenomenon.

Wigley FM, Flavahan NA.

N Engl J Med. 2016 Aug 11;375(6):556-65. doi: 10.1056/NEJMra1507638. Review. No abstract available.

PMID:
27509103
30.

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM; Sclerodema Lung Study II Investigators.

Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25.

31.

Risk of Digital Vascular Events in Scleroderma Patients Who Have Both Anticentromere and Anti-Interferon-Inducible Protein 16 Antibodies.

McMahan ZH, Wigley FM, Casciola-Rosen L.

Arthritis Care Res (Hoboken). 2017 Jun;69(6):922-926. doi: 10.1002/acr.22978.

32.

Unique Abnormalities in Right Ventricular Longitudinal Strain in Systemic Sclerosis Patients.

Mukherjee M, Chung SE, Ton VK, Tedford RJ, Hummers LK, Wigley FM, Abraham TP, Shah AA.

Circ Cardiovasc Imaging. 2016 Jun;9(6). pii: e003792. doi: 10.1161/CIRCIMAGING.115.003792. Epub 2016 Jun 7.

33.

Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension.

Hsu S, Houston BA, Tampakakis E, Bacher AC, Rhodes PS, Mathai SC, Damico RL, Kolb TM, Hummers LK, Shah AA, McMahan Z, Corona-Villalobos CP, Zimmerman SL, Wigley FM, Hassoun PM, Kass DA, Tedford RJ.

Circulation. 2016 Jun 14;133(24):2413-22. doi: 10.1161/CIRCULATIONAHA.116.022082. Epub 2016 May 11.

34.

Enrichment of Scleroderma Vascular Disease-Associated Autoantigens in Endothelial Lineage Cells.

McMahan ZH, Cottrell TR, Wigley FM, Antiochos B, Zambidis ET, Park TS, Halushka MK, Gutierrez-Alamillo L, Cimbro R, Rosen A, Casciola-Rosen L.

Arthritis Rheumatol. 2016 Oct;68(10):2540-9. doi: 10.1002/art.39743.

35.

Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma.

Fava A, Cimbro R, Wigley FM, Liu QR, Rosen A, Boin F.

Arthritis Res Ther. 2016 May 4;18(1):99. doi: 10.1186/s13075-016-0993-2.

36.

Thrombotic complications after radial arterial line placement in systemic sclerosis: A case series.

Paik JJ, Hirpara R, Heller JA, Hummers LK, Wigley FM, Shah AA.

Semin Arthritis Rheum. 2016 Oct;46(2):196-199. doi: 10.1016/j.semarthrit.2016.03.015. Epub 2016 Mar 31.

37.

Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients.

Wu M, Assassi S, Salazar GA, Pedroza C, Gorlova OY, Chen WV, Charles J, Taing ML, Liao K, Wigley FM, Hummers LK, Shah AA, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Zhou X, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Fritzler MJ, Molitor JA, Segal BM, Movahedian M, Martín J, Varga J, Mayes MD.

Arthritis Res Ther. 2016 Jan 20;18:20. doi: 10.1186/s13075-016-0923-3.

38.

Anti-Interferon-Inducible Protein 16 Antibodies Associate With Digital Gangrene in Patients With Scleroderma.

McMahan ZH, Shah AA, Vaidya D, Wigley FM, Rosen A, Casciola-Rosen L.

Arthritis Rheumatol. 2016 May;68(5):1262-71. doi: 10.1002/art.39558.

39.

Development and Validation of the Body Concealment Scale for Scleroderma.

Jewett LR, Malcarne VL, Kwakkenbos L, Harcourt D, Rumsey N, Körner A, Steele RJ, Hudson M, Baron M, Haythornthwaite JA, Heinberg L, Wigley FM, Thombs BD; Canadian Scleroderma Research Group.

Arthritis Care Res (Hoboken). 2016 Aug;68(8):1158-65. doi: 10.1002/acr.22819.

40.

Symptomatic and Electrodiagnostic Features of Peripheral Neuropathy in Scleroderma.

Paik JJ, Mammen AL, Wigley FM, Shah AA, Hummers LK, Polydefkis M.

Arthritis Care Res (Hoboken). 2016 Aug;68(8):1150-7. doi: 10.1002/acr.22818.

41.

Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study.

Riehm KE, Kwakkenbos L, Carrier ME, Bartlett SJ, Malcarne VL, Mouthon L, Nielson WR, Poiraudeau S, Nielsen K, Baron M, Frech T, Hudson M, Pope J, Sauve M, Suarez-Almazor ME, Wigley FM, Thombs BD; Scleroderma Patient-Centered Intervention Network Investigators.

Arthritis Care Res (Hoboken). 2016 Aug;68(8):1195-200. doi: 10.1002/acr.22807.

42.

Editorial: Scleroderma: Bringing a Disease From Black-and-White Into Technicolor.

Ligon CB, Wigley FM.

Arthritis Rheumatol. 2015 Dec;67(12):3101-3. doi: 10.1002/art.39310. No abstract available.

43.

Biomarkers of pulmonary hypertension in patients with scleroderma: a case-control study.

McMahan Z, Schoenhoff F, Van Eyk JE, Wigley FM, Hummers LK.

Arthritis Res Ther. 2015 Aug 6;17:201. doi: 10.1186/s13075-015-0712-4.

44.

Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma.

Shah AA, Montagne J, Oh SY, Wigley FM, Casciola-Rosen L.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S123-6. Epub 2015 Aug 5.

45.

Management of Raynaud Phenomenon and Digital Ulcers in Scleroderma.

Cappelli L, Wigley FM.

Rheum Dis Clin North Am. 2015 Aug;41(3):419-38. doi: 10.1016/j.rdc.2015.04.005. Epub 2015 May 23. Review.

PMID:
26210127
46.

Case 8-2015: A Man with Multiple Myeloma, Skin Tightness, Arthralgias, and Edema.

Wigley F, Nazarian RM.

N Engl J Med. 2015 Jun 18;372(25):2466. doi: 10.1056/NEJMc1504514. No abstract available.

PMID:
26083221
47.

Spectrum of Muscle Histopathologic Findings in Forty-Two Scleroderma Patients With Weakness.

Paik JJ, Wigley FM, Lloyd TE, Corse AM, Casciola-Rosen L, Shah AA, Boin F, Hummers LK, Mammen AL.

Arthritis Care Res (Hoboken). 2015 Oct;67(10):1416-25. doi: 10.1002/acr.22620.

48.

Case records of the Massachusetts General Hospital. Case 8-2015. A 68-year-old man with multiple myeloma, skin tightness, arthralgias, and edema.

Wigley F, Friday RP, Shepard JA, Nazarian RM.

N Engl J Med. 2015 Mar 12;372(11):1056-67. doi: 10.1056/NEJMcpc1409840. No abstract available.

PMID:
25760359
49.

Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception.

Hughes M, Snapir A, Wilkinson J, Snapir D, Wigley FM, Herrick AL.

Rheumatology (Oxford). 2015 Aug;54(8):1443-7. doi: 10.1093/rheumatology/kev002. Epub 2015 Mar 9.

PMID:
25752312
50.

Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma.

Shah AA, Hummers LK, Casciola-Rosen L, Visvanathan K, Rosen A, Wigley FM.

Arthritis Rheumatol. 2015 Apr;67(4):1053-61. doi: 10.1002/art.39022.

Supplemental Content

Loading ...
Support Center